Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

is year.

As previously announced, the Phase 3 trial will evaluate the efficacy, safety, and pharmacodynamics of Amigal in males and females with Fabry disease. The trial will consist of a six-month double-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects who are naive to enzyme replacement therapy (ERT) or who have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day.

The primary endpoint will be the change in the amount of kidney interstitial capillary GL-3 as measured in kidney biopsies using histology. Secondary endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour urine protein).

Additionally, the FDA and Amicus reached agreement on an improved methodology for the histological evaluation of GL-3 in the kidney biopsies. An analysis of the Phase 2 and Phase 2 extension study biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had detectable interstitial capillary GL-3 and that reductions were observed in eight of the nine responders.

It is expected that approximately 30 clinical sites worldwide will participate in this trial.

Plicera(TM) (afegostat tartrate) for the treatment of Gaucher Disease

A Phase 2 clinical trial of the Company's investigational drug Plicera is ongoing. This 6-month study is designed to evaluate safety, dosing, and preliminary efficacy, as measured by the standard endpoints in Gaucher disease. The Company expects to report the results early in the fourth quarter of 2009.

Amicus continues to work closely with its partner, Shire HGT, to prepare for Phase 3 development
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... SEABROOK, N.H. , May 22, 2013 /PRNewswire/ ... of the Year 2013" by Business NH Magazine.  ... recognized Granite State organizations that distinguish themselves with ... are very proud to receive this honor," said ... Superior Controls.  "As with any recognition, this award ...
(Date:5/22/2013)... Toronto, Ontario (PRWEB) May 22, 2013 ... of advanced sound therapy for tinnitus treatment. AudioNotch ... Destination Hearing . With clinic locations in both ... trusted provider of audiology and hearing services. AudioNotch's ... Zabell locations. , Upon entering a Destination Hearing ...
(Date:5/22/2013)... Envera announced today that Michael McErlean ... McErlean has an extensive background in cell production and ... career. , Mike Matheny, President and Owner ... Mike join our team”. “Mike’s background is perfectly suited ... and downstream processing equipment”, added Matheny. “Mike’s hands ...
(Date:5/21/2013)... , May 22, 2013 ... drug-only formulation of glycopyrronium bromide designed using Prosonix, particle ... company developing a portfolio of inhaled Respiratory Medicines ... study with PSX1002 that will assess its effect on ... doses in patients with moderate to severe chronic obstructive ...
Breaking Biology Technology:Superior Controls of Seabrook, NH named Business of the Year for 2013 by Business NH Magazine 2AudioNotch Tinnitus Treatment Launches Partnership With Destination Hearing 2Envera Appoints Michael McErlean Fermentation Manager 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
... Mass.,  Feb. 4, 2011 The ALS ... elected Anil Godhwani, a successful Silicon Valley entrepreneur, to ... "nonprofit biotechnology" organization with a mission to discover and ... sclerosis (ALS, Lou Gehrig,s Disease). (Logo: ...
... Pharmacyclics, Inc. (Nasdaq: PCYC ) today ... second quarter that ended December 31, 2010.Recent Developments & ... Btk Inhibitor PCI-32765 in B-cell malignanciesPharmacyclics has designed a ... lymphocytic leukemia and diffuse large B-cell lymphoma to inform ...
... Boston College has been awarded a $1 million grant ... of university researchers developing a new microscope that uses ... and macroscopic matter with significantly improved clarity. The ... new class of microscopes known as "superlenses," which function ...
Cached Biology Technology:ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 2Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 3Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 4Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 5Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 6Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 7Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 8Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011 9Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2
(Date:5/22/2013)... of pollinating insects and wild plants have slowed in ... led by the University of Leeds and the Naturalis ... dramatic reductions in the diversity of species in Britain, ... , But the picture brightened markedly after 1990, with ... bees, hoverflies and wild plants. , Professor ...
(Date:5/21/2013)... long time that some creatures evolve more quickly than ... But it may be that height plays a role, ... U. S. National Evolutionary Synthesis Center. , In ... journal Nature Communications , Lanfear and colleagues report ... a database of global patterns in plant height for ...
(Date:5/21/2013)... considered in the management of natural resources, and ... help them recognize and respond to the relationships ... , Place-Based Conservation: Perspectives from the Social ... Northwest Research Station,s Linda Kruger, can help managers ... is published by Springer Verlag and is available ...
Breaking Biology News(10 mins):Encouraging signs for bee biodiversity 2Encouraging signs for bee biodiversity 3Small but speedy: Short plants live in the evolutionary fast lane 2
... in the Earth and its atmosphere, such as melting polar ... of global climate change. But changes in climate can wreak ... habitat for plant and animal species. In a series of ... Meeting, climate change scientists will discuss how temperature-induced habitat loss ...
... into an epidemic, reflected in soaring rates of type ... elevated cholesterol. What hasn,t been as clear is ... a pediatric research program on Friday suggested obesity prevention ... children reach a "tipping point" in a progression that ...
... a genetically induced lack of filaggrin, a key protein ... the origin of allergies. In a large study on ... Mnchen and the Technische Universitt Mnchen found that about ... filaggrin gene, which raise the risk to develop atopic ...
Cached Biology News:Climate change and species distributions 2Climate change and species distributions 32 years old -- a childhood obesity tipping point? 2When our protective armor shows weakness 2
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
EDG-6 (1)...
Complexin-1/2 (FL-134)...
Biology Products: